Physician profile
Kent Erickson
NPI 1336209873
$11,117.62
in general payments reported to CMS, 2019-2025
58 companies · $1,667 in 2025
The $1,667 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $983 · 2021: $2,648 · 2022: $1,278 · 2023: $1,346 · 2024: $1,934 · 2025: $1,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,946.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,290.45 | 2021 | |
| Novo Nordisk INC | $1,146.69 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $984.39 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $853.29 | 2019-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $779.06 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $734.00 | 2021-2025 | |
| Glaxosmithkline, LLC. | $630.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $624.64 | 2019-2025 | Jardiance |
| Dexcom, INC. | $459.28 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Daiichi Sankyo INC. | $352.37 | 2019-2022 | |
| Pfizer INC. | $350.28 | 2019-2025 | |
| Allergan, INC. | $298.72 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $233.84 | 2020-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $223.51 | 2019-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $222.91 | 2023-2025 | Cologuard Collection Kit |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.